Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy
Phase of Trial: Phase III
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Immune globulin (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Registrational; Therapeutic Use
- Sponsors Octapharma
- 03 Aug 2017 Status changed from not yet recruiting to recruiting.
- 09 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.
- 06 Apr 2017 Planned initiation date changed from 1 Mar 2017 to 1 Apr 2017.